Patient and Family sessions at the Fourth BHD Symposium

Around 30 patients and family members participated in the Fourth BHD Symposium in Cincinnati, Ohio last month. Such a record turnout had a significant effect on the flow of the Symposium – for example, by providing researchers with many opportunities to meet and engage with families – and is evidence of an active BHD community. … Read more

Highlights of the Fourth BHD Symposium

At the end of March, more than 90 BHD researchers, clinicians and patients attended the Fourth BHD Symposium, which was held in Cincinnati, Ohio, USA. The Symposium was the largest BHD meeting to date and it was a huge success. Talks were held in the impressive Vontz Center at the University of Cincinnati, which was … Read more

10th International Congress on Targeted Anticancer Therapies

At the beginning of March, Amsterdam hosted the 10th International Congress on Targeted Anticancer Therapies, organised by the NDDO Education Foundation. The congress discussed all aspects of targeted therapy, from the identification of targets and the design of drugs, to clinical trials and the observed benefits for patients. Dr Elizabeth Eisenhauer of Queen’s University, Canada … Read more

Characterisation of the RCC susceptibility locus on chromosome 11

A blog post from January last year described a paper by Purdue et al. (2011) in which a genome-wide association study (GWAS) identified two renal cell carcinoma (RCC) susceptibility loci within HIF2α (on chromosome 2) and an uncharacterised intergenic region (on chromosome 11). A recent study using VHL-deficient RCC cells has taken this work further by showing that this intergenic region contains a number … Read more